# DOSISPHERE-01 (NCT02582034)

> Internal Radiation Therapy for Hepatocellular Carcinomas With Therasphere: Optimized Dosimetry Versus Standard Dosimetry

No report yet. It can be ordered.

- Drugs tested: none (the trial tests no drug)
- Indication: locally advanced hepatocellular carcinoma

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02582034
- Phase: PHASE2
- Status: COMPLETED
- Sponsor: Center Eugene Marquis
- Conditions: Adenoma, Liver Cell
- Interventions: Optimized Internal Radiation Therapy; Standard Internal Radiation Therapy
- Enrollment: 56
- Primary outcome: The primary endpoint is to compare the response rate of the treated lesion at the first radioembolization, evaluated using European Association for the Study of the Liver (EASL) criteria of yttrium-90 marked glass microspheres SIRT

## Indexed commentary on DOSISPHERE-01 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 6

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=dosisphere-01-nct02582034